The dawning of dual-acting incretin drugs
- PMID: 34272516
- DOI: 10.1038/s41574-021-00540-y
The dawning of dual-acting incretin drugs
Comment on
-
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. N Engl J Med. 2021. PMID: 34170647 Clinical Trial.
-
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. Lancet. 2021. PMID: 34186022 Clinical Trial.
References
Original articles
-
- Frías, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2107519 (2021) - DOI - PubMed
-
- Rosenstock, J. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet https://doi.org/10.1016/S0140-6736(21)01324-6 (2021) - DOI - PubMed
Related articles
-
- Perreault, L. et al. Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 17, 364–377 (2021) - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical